The first fixed-dose triple combo medication for COPD is introduced by Lupin.

In India, COPD affects over 37 million people and is one of the main causes of…

Why are Indian pharmaceutical firms making biologics investments?

Indian pharmaceutical companies are making investments in biologics in response to the growing need for safe…

To speed up drug research, Sai Life Sciences teams up with Dassault Systèmes.

Indian contract research, development, and manufacturing organization (CDMO) Sai Life Sciences has teamed up with Dassault…

Novartis eyes rare disease market in India, runs 17 clinical programs

In 2022, Novartis invested around $10 billion in overall research and development (R&D) and has already…

Healthcare and Pharma Preview: India biz to drive sector in Q4

Hospitals to recover from sluggish Q3; diagnostics growth rate at pre-Covid levels. Analysts feel that revenue…